Acute Graft Versus Host Disease
3
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
3
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Design TherapeuticsCARLSBAD, CA
1 program1
Adult Allogeneic Mesenchymal cells from adipose tissue.Phase 1/21 trial
Active Trials
AmgenTHOUSAND OAKS, CA
1 program1
Recombinant Human Keratinocyte Growth FactorPhase 1/21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Design TherapeuticsAdult Allogeneic Mesenchymal cells from adipose tissue.
Astex Pharmaceuticalspentostatin for injection
AmgenRecombinant Human Keratinocyte Growth Factor
Clinical Trials (3)
Total enrollment: 7 patients across 3 trials
Clinical Trial With MSC for Graft Versus Host Disease Treatment
Start: Feb 2017Est. completion: Jan 2022
Phase 1/2Completed
Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD
Start: Jan 2002Est. completion: Nov 2005
Phase 1/2Terminated
Phase I/II Trial rHuKFG for the Treatment of Steroid Refractory Gastrointestinal Acute GVHD
Start: Oct 2000Est. completion: Jan 20037 patients
Phase 1/2Terminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space